Zora Biosciences

Executive Summary

Zora Biosciences Oy is a Finnish diagnostics company specializing in cardiometabolic disease markers using mass spectrometry. Founded in 2007 and based in Espoo, the company develops high-throughput clinical diagnostic tests and operates its own reference laboratory. With a focus on converting lipid and metabolite biomarkers into robust, value-added tests, Zora commercializes its products through international partnerships and direct lab services. While the company remains private with no disclosed funding or valuation, its established platform and niche focus position it as a potential player in precision cardiometabolic diagnostics. The lack of recent public milestones suggests a steady-state operation, but future growth could be driven by new test launches or strategic collaborations.

Upcoming Catalysts (preview)

• Q3 2026Launch of new high-sensitivity cardiovascular risk test60% success
• Q4 2026CE-IVDR certification for existing diagnostic panel70% success
• TBDPartnership with a major pharma for drug-diagnostic co-development40% success